Lev Pharmaceuticals News
Most Popular Lev Pharmaceuticals Story
ViroPharma to buy Lev for $442M
ViroPharma has forged a deal to buy Lev Pharmaceuticals - a developer focused on developing inflammatory therapies -- for $442 million. The deal provides ViroPharma with Lev's Cinryze program, a... Read more...
Latest Headlines
- October 13, 2008
- July 15, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
